Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
1-1-2020

nab-paclitaxel plus durvalumab in patients with previously treated
advanced stage non-small cell lung cancer (ABOUND.2L+)
Daniel Morgensztern
Manuel Cobo Dols
Santiago Ponce Aix
Pieter E Postmus
Jaafar Bennouna

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Authors
Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, Pieter E Postmus, Jaafar Bennouna, Jürgen
R Fischer, Oscar Juan-Vidal, David J Stewart, Andrea Ardizzoni, Rafia Bhore, Marianne Wolfsteiner, Martin
Reck, Denis Talbot, Ramaswamy Govindan, and Teng Jin Ong

ORIGINAL RESEARCH
published: 11 February 2021
doi: 10.3389/fonc.2020.569715

nab-Paclitaxel Plus Durvalumab in
Patients With Previously Treated
Advanced Stage Non-small Cell Lung
Cancer (ABOUND.2L+)
Daniel Morgensztern 1*, Manuel Cobo Dols 2 , Santiago Ponce Aix 3 , Pieter E. Postmus 4 ,
Jaafar Bennouna 5 , Jürgen R. Fischer 6 , Oscar Juan-Vidal 7 , David J. Stewart 8 ,
Andrea Ardizzoni 9 , Rafia Bhore 10 , Marianne Wolfsteiner 11 , Martin Reck 12 , Denis Talbot 13 ,
Ramaswamy Govindan 1 and Teng Jin Ong 10 on behalf of the ABOUND.2L+ investigators
1

Edited by:
Qing Zhou,
Guangdong Provincial People’s
Hospital Lung Cancer Institute, China
Reviewed by:
Vincent Lam,
Johns Hopkins University,
United States
Dwight Hall Owen,
The Ohio State University,
United States
*Correspondence:
Daniel Morgensztern
danielmorgensztern@wustl.edu
Specialty section:
This article was submitted to
Thoracic Oncology,
a section of the journal
Frontiers in Oncology
Received: 04 June 2020
Accepted: 14 September 2020
Published: 11 February 2021
Citation:
Morgensztern D, Dols MC, Ponce
Aix S, Postmus PE, Bennouna J,
Fischer JR, Juan-Vidal O, Stewart DJ,
Ardizzoni A, Bhore R, Wolfsteiner M,
Reck M, Talbot D, Govindan R and
Ong TJ (2021) nab-Paclitaxel Plus
Durvalumab in Patients With
Previously Treated Advanced Stage
Non-small Cell Lung Cancer
(ABOUND.2L+).
Front. Oncol. 10:569715.
doi: 10.3389/fonc.2020.569715

Frontiers in Oncology | www.frontiersin.org

Washington University School of Medicine, St Louis, MO, United States, 2 Hospital Universitario Málaga Regional, Instituto
de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain, 3 Unidad de Investigación Clínica de Cáncer Pulmón
H12O-CNIO, Madrid, Spain, 4 Clatterbridge Cancer Center, Liverpool, United Kingdom, 5 Centre René Gauducheau Centre
de Lutte Contre Le Cancer Nantes Atlantique, Nantes, France, 6 Lungenklinik Löwenstein gGmbH, Löwenstein, Germany,
7
Universitari i Politécnic La Fe, Valencia, Spain, 8 Ottawa Hospital, Ottawa, ON, Canada, 9 Azienda Ospedaliero Universitaria
Di Bologna—Policlinico S. Orsola-Malpighi, Bologna, Italy, 10 Bristol Myers Squibb, Princeton, NJ, United States,
11
Pharmaceutical Research Associates Inc. (PRA) Health Sciences, Lenexa, KS, United States, 12 LungenClinic,
Grosshansdorf, Germany, 13 Churchill Hospital, Oxford, United Kingdom

Background: The standard therapy for advanced stage non-small cell lung cancer
(NSCLC) with no actionable gene alterations is a platinum-based chemotherapy doublet
and immune checkpoint blocker (ICB), either concurrently or sequentially, followed by
docetaxel at the time of tumor progression. However, more effective treatments are
needed. We evaluated the nab-paclitaxel and durvalumab combination in patients with
previously treated advanced stage NSCLC.
Methods: Patients with advanced stage NSCLC previously treated with one line of
platinum-based doublet with or without an ICB and no activating EGFR mutations or
ALK translocations received nab-paclitaxel 100 mg/m2 (days 1 and 8) plus durvalumab
1,125 mg (day 15) every 21 days. The primary endpoint was progression-free survival
(PFS). Key secondary endpoints included overall survival (OS) and safety.
Results: Between February 2016 and December 2016, 79 patients were enrolled.
The median age was 63 years. Most patients were males (68.4%), had non-squamous
histology (69.6%), and had no prior ICB treatment (88.6%). The median PFS was 4.5
months; median OS was 10.1 months. A post hoc analysis of survival by prior ICB
treatment revealed a median PFS and OS of 4.4 and 9.9 months, respectively, in ICBnaive patients and 6.9 months and not estimable, respectively, in patients previously
treated with ICB. The most common treatment-emergent adverse events were asthenia
(46.2%) and diarrhea (34.6%); four treatment-related deaths (5.1%) occurred.
Conclusions: The nab-paclitaxel and durvalumab combination is feasible and
demonstrated antitumor activity without new safety signals. Additional studies using
taxanes and ICB in patients with previously treated NSCLC are warranted.
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Clinical Trial Registration: ClinicalTrials.gov registration (NCT02250326).
EudraCT number: 2014-001105-41
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INTRODUCTION

nab-paclitaxel and durvalumab, which was non-randomized and
added as an amendment.

The standard initial therapy for patients with advanced
stage non-small cell lung cancer (NSCLC) and no actionable
gene alterations includes platinum-based chemotherapy
doublet and immune checkpoint blockers (ICB) either
sequentially or concurrently (1, 2). For patients previously
treated with chemotherapy alone, monoclonal antibodies
against programmed death-1 (PD-1) or its ligand (PD-L1) are
associated with improved overall survival (OS) when compared
to docetaxel in the second-line setting, although prolonged
benefit is observed only in a small percentage of patients (3–6).
For those already treated with both chemotherapy and ICB,
docetaxel with or without ramucirumab remains the standard
option (7). Response rates and survival, however, remain
poor for the majority of patients treated with second-line
ICB monotherapy or docetaxel, indicating the need for new
treatment options.
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a
cremophor-free formulation that can be administered without
dexamethasone premedication (8), is one of the recommended
drugs for locally advanced or metastatic NSCLC in combination
with carboplatin, with or without pembrolizumab, in the first-line
setting for patients who are not candidates for curative surgery
or radiation therapy (2, 9). Single-agent nab-paclitaxel has been
associated with promising results in previously treated patients
with metastatic NSCLC (10, 11) and better tolerability compared
with docetaxel in a randomized clinical trial for patients with
metastatic breast cancer (12).
Durvalumab is a human IgG1 monoclonal antibody against
PD-L1, approved as consolidation therapy after chemoradiation
in patients with stage III NSCLC (13). In patients with advanced
stage NSCLC, single-agent durvalumab is associated with similar
activity and safety profiles when compared with other ICBs (14).
Based on both preclinical (15) and clinical (16–18) studies
demonstrating a benefit from concurrent chemotherapy and
ICB in NSCLC, we postulated that the same principles may
apply to patients treated with nab-paclitaxel after progression on
platinum-based chemotherapy with or without ICB.
ABOUND.2L+ was a randomized clinical trial comparing
nab-paclitaxel alone or in combination with CC-486, an
oral formulation of azacitidine (19). The study showed no
benefit from the addition of azacitidine to nab-paclitaxel in
the randomized cohorts of the study, although single-agent
nab-paclitaxel was associated with a tolerable safety profile
and promising outcomes, including response rates, median
progression-free survival (PFS), and median OS of 16.3%, 4.2,
and 17.0 months, respectively. Here we present the results
of the third arm of the study evaluating the combination of
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MATERIALS AND METHODS
Patients
Eligible patients were 18 years of age or older and had
histologically or cytologically confirmed advanced stage NSCLC,
radiologically documented measurable disease by Response
Evaluation Criteria In Solid Tumors (RECIST) 1.1, an Eastern
Cooperative Oncology Group performance status 0 or 1,
adequate hematologic, renal, and hepatic function, and no
other current active malignancy requiring anticancer therapy.
One prior line of platinum-based chemotherapy regimen for
metastatic or recurrent disease was allowed, with the exception of
taxanes, which were allowed only if used in the adjuvant setting
more than 12 months prior to enrollment into the trial. Prior use
of ICBs, either as a component of the first-line therapy or in the
second line, was allowed. Key exclusion criteria included known
activating EGFR mutations or ALK translocations, peripheral
neuropathy grade 2 or higher by the National Cancer Institute
Common Terminology Criteria for Adverse Events (NCICTCAE) version 4.0, active or prior documented autoimmune
or inflammatory disorder, use of systemic immunosuppressive
therapy within 14 days from starting durvalumab except for
corticosteroids, at doses up to 10 mg per day of prednisone
or its equivalent, and brain metastases unless asymptomatic
and clinically stable for at least 8 weeks following completion
of therapy.
The study was approved by the institutional review board
or independent ethics committee at participating sites and
conducted in accordance with the principles of good clinical
practice and the Declaration of Helsinki. All patients provided
written informed consent prior to treatment initiation.

Study Design
This was an open-label phase II study. Initially, patients were
randomized 1:1 to receive nab-paclitaxel 100 mg/m2 on days 8
and 15 plus CC-486 200 mg on days 1 to 14 or nab-paclitaxel
100 mg/m2 alone on days 1 and 8 of each 21-day cycle
(19). After enrollment for the nab-paclitaxel alone and nabpaclitaxel plus CC-486 arms was completed, the protocol was
amended to include a third arm, which enrolled patients with
advanced stage non-squamous or squamous NSCLC and one
prior platinum-based chemotherapy. Patients were assigned to
this arm and received nab-paclitaxel 100 mg/m2 infused over
30 min on days 1 and 8 plus durvalumab 1,125 mg infused
over 1 h on day 15, with the cycles repeating every 21 days.
Hence, randomization did not occur between the nab-paclitaxel
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FIGURE 1 | CONSORT diagram.

total of approximately 80 patients), all patients were assigned to
the nab-paclitaxel plus durvalumab arm until approximately 80
patients were enrolled in that arm. The statistical assumptions
used were identical to the nab-paclitaxel plus CC-486 arm.
An interim analysis for PFS comparing the nab-paclitaxel
plus durvalumab and nab-paclitaxel monotherapy arms was
conducted when approximately 30 PFS events were observed in
the nab-paclitaxel plus durvalumab combination arm.

plus durvalumab and nab-paclitaxel alone arms. Treatment was
continued until documented tumor progression, unacceptable
toxicity, withdrawal of consent, lost to follow-up, or death.

Endpoints and Assessments
The primary endpoint was the duration of PFS in the intent-totreat (ITT) population, defined as the time from date of treatment
initiation to the date of disease progression, based on investigator
assessment using RECIST version 1.1, or death from any cause.
Secondary endpoints included OS, defined as the time between
the first treatment and death from any cause, overall response rate
(ORR), disease control rate (DCR), and safety. Imaging studies
with computer tomography scans were performed at baseline
and every 42 days until treatment discontinuation. All patients
who received at least one treatment dose underwent safety
analysis, with documentation of treatment-emergent adverse
events (TEAEs) graded based on NCI-CTCAE version 4.0.

RESULTS
Patients
Between September 2016 and December 2016, 99 patients were
screened and 79 were enrolled into the study (Figure 1). The
median age was 63 years (range 29–84 years); most patient were
males (68.4%) and had non-squamous histology (69.6%) and
no prior use of ICB (88.6%) (Table 1). Prior chemotherapies
included a platinum (97.5%), pemetrexed (50.6%), vinorelbine
(25.3%), and gemcitabine (26.6%). The median duration of prior
platinum plus pemetrexed (39 patients) was 10.4 weeks (range
1.6–43.4 weeks). In total, nine patients (11.4%) received prior
ICB, which was their most immediate prior line of therapy.
Among these nine patients, six received nivolumab (66.7%), two
received pembrolizumab (22.2%), and one received avelumab
(11.1%), with the latter in the first-line setting. Of these nine
patients, eight (88.9%) received prior ICB monotherapy. The
remaining patient (11.1%) received prior combination therapy
with ICB and carboplatin. One patient did not receive the
study treatment. In total, 63 patients (80.8%) discontinued
treatment due to progressive disease (36 [46.2%]), death (12
[15.4%]), patient withdrawal (5 [6.4%]), clinical progression

Statistical Analyses
The median PFS and median OS were estimated using the
Kaplan-Meier estimates with corresponding two-sided 95%
confidence intervals (CI). The sample size estimation was based
on the expected median PFS of 4.25 months for nab-paclitaxel
plus durvalumab and 2.5 months for nab-paclitaxel alone based
on historical data with docetaxel alone (7, 20, 21).
In the randomized part of the trial, it was estimated that a
total of 160 patients would be needed to observe 120 PFS events,
which would have provided 80% power to detect a hazard ratio of
0.60 using a one-sided test at the 2.5% level of significance. After
enrollment in the nab-paclitaxel plus CC-486 and nab-paclitaxel
monotherapy arms was completed (each arm had reached a
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(Figure 3B). The median OS was 9.9 months (95% CI, 7.52–
12.94 months) in ICB-naive patients and NE in those previously
treated with ICB (Figure 3C). Among ICB-naive patients, the
median OS for squamous and non-squamous histologies was 8.9
months (95% CI, 2.99 months-NE) and 10.3 months (95% CI,
6.57 months-NE), respectively (Figure 3D).
The median percentage change from baseline in sum of
diameters of target lesions was −17.3% (range −100.0 to
+65.4%) for ICB-naive patients and −21.4% (range −76.2
to +28.1%) for those previously treated with ICB (Figure 4).
Among ICB-naive patients, one achieved CR (1.4%), 17 achieved
PR (24.6%), and 30 had SD (43.5%) for a DCR of 69.6%. Of the
remaining patients, 10 had PD (14.5%) and 11 (15.9%) had no
post-treatment response assessment. Among patients previously
treated with ICB, four achieved PR (44.4%), four achieved SD
(44.4%), and one had PD (11.1%).

TABLE 1 | Demographic and baseline clinical characteristics.
Characteristic

nab-Paclitaxel + Durvalumab (N = 79)

Age, years
Mean (SD)

62.7 (10.74)

Median (range)

63.0 (29–84)

Male sex, number (%)

54 (68.4%)

ECOG performance status, number (%)
0

18 (22.8%)

1

61 (77.2%)

Stage IV disease, number (%)

75 (94.9%)

Histology
Squamous

23 (29.1%)

Non-squamous

55 (69.6%)

Not specified

1 (1.3%)

Prior therapy
No prior ICB

70 (88.6%)

Prior ICB

9 (11.4%)a

Treatment Exposure
The median number of cycles and treatment duration were 7
(range 1–21) and 24.4 weeks (range 1.4–66.1 weeks), respectively.
The median cumulative doses of nab-paclitaxel and durvalumab
were 1,250 mg/m2 and 6,750 mg, respectively. Dose reductions
for nab-paclitaxel due to toxicity occurred in 11 patients (14.1%);
per protocol, durvalumab dose reductions were not allowed.
Dose delays of nab-paclitaxel and durvalumab occurred in 39
patients (50%) and 24 patients (30.8%), respectively.

a One

patient with prior ICB treatment received first-line avelumab without platinumbased chemotherapy.
ECOG, Eastern Cooperative Oncology Group; ICB, immune checkpoint blocker.

(4 [5.1%]), adverse events (4 [5.1%]), and other reasons (2
[2.6%]). The adverse events (AEs) leading to nab-paclitaxel and
durvalumab discontinuation were pneumonitis, urinary tract
infection, and Pneumocystis jirovecii pneumonia (one patient
each) and increased white blood cell count, abnormal liver
function, localized edema, and peripheral edema (one patient).
The median follow-up for survival was 12.9 months.

Safety
All patients developed at least one TEAE, with grade 3 or 4 TEAEs
occurring in 43 patients (55.1%) (Table 2). The most common
TEAEs of any grade were asthenia (46.2%), diarrhea (34.6%), and
decreased appetite (33.3%), while the most common grade 3 or
4 TEAEs were asthenia (12.8%), dyspnea (7.7%), and pneumonia
(7.7%). Peripheral neuropathy was seen in 29 patients (37.2%), of
which 3 (3.8%) were grade 3 or 4.
Immune-related TEAEs of grade 3 or 4 were observed in seven
patients (9.0%). The grade 3 or 4 immune-related TEAEs were
diarrhea (1 [1.3%]), rash (2 [2.6%]), pneumonitis (1 [1.3%]),
and adrenal insufficiency (3 [3.8%]). Among the nine patients
who received prior ICB, immune-related TEAEs of grade 3 or
4 were observed in two patients (22.2%). The grade 3 or 4
immune-related TEAEs were adrenal insufficiency and rash (1
patient [11.1%] each). Other AEs of interest included grade 1 or
2 dermatitis (10.3%) and thyroid dysfunction (hypothyroidism,
6.4%; hyperthyroidism, 2.6%; thyroiditis, 1.3%).
Overall, four patients (5.1%) experienced a grade 5 TEAE
suspected to be treatment related. The specific grade 5 treatmentrelated TEAEs were pneumonitis, pulmonary hemorrhage,
Pneumocystis jirovecii pneumonia, and clinical deterioration.

Efficacy
For the primary analysis of investigator-assessed PFS in the ITT
population, 56 patients (70.9%) had progressive disease (PD) or
died. The median PFS was 4.5 months (95% CI, 3.5–5.9 months),
with an estimated PFS rate at 12 months of 25.7% (95% CI,
16.3–36.2%; Figure 2A).
For the OS analysis in the ITT population, 44 patients (55.7%)
had died. The median OS was 10.1 months (95% CI, 7.8 monthsnot estimable [NE]), with estimated survival at 12 months of
43.8% (95% CI, 32.3–54.7%; Figure 2B).
The ORR was 27.8% (95% CI, 18.3–39.1%), with complete
response (CR) in one patient (1.3%) and partial response (PR) in
21 patients (26.6%). The DCR was 70.9% (95% CI, 59.6–80.6%),
with 34 patients (43.0%) achieving stable disease (SD).
Due to the heterogeneity of the patient population, a post
hoc analysis was performed to evaluate outcomes according to
prior ICB treatment and histology in the 78 patients with known
histology. The median PFS was 4.4 months (95% CI, 2.96–5.68
months) in ICB-naive patients and 6.9 months (95% CI, 1.38
months-NE) in patients previously treated with ICB (Figure 3A).
Among ICB-naive patients, the median PFS was 5.6 months
(95% CI, 1.3–7.8 months) in those with squamous histology
and 4.1 months (2.7–5.7 months) in those with non-squamous
histology, with corresponding 12-month PFS of 27.1% (95%
CI, 9.0–49.2%) and 20.9% (95% CI, 10.6–33.6%), respectively
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DISCUSSION
The median PFS of 4.5 months exceeded the pre-specified
threshold, and the response rate of 27.8% is higher than
previously described in patients treated with either docetaxel or
ICB monotherapy (3–6).
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FIGURE 2 | Investigator-assessed PFS (A) and OS (B) in the intent-to-treat population. NE, not estimable; OS, overall survival; PFS, progression-free survival.

by upregulating mannose-6-phosphate receptors on tumor
cells, which increases the permeability of the membrane to
granzyme B, leading to cancer cell death independent from
perforin (26). Since nab-paclitaxel does not require the use
of premedication with corticosteroids, it may be a better
partner for combination with ICB when compared with other
taxanes since, at least in patients treated with single-agent ICB,
use of corticosteroids at doses of 10 mg or higher has been
associated with worse outcomes compared with no use within 30
days (27).
There are limited data on the combination of taxanes and
ICB without platinum in patients with previously treated NSCLC.
In a small phase Ib study evaluating the combination of
chemotherapy and nivolumab 10 mg/kg every 3 weeks, there
were six patients previously treated with platinum-doublets
who were enrolled into the docetaxel arm (28). One patient

There are increasing data suggesting that the efficacy of
conventional chemotherapy drugs relies not only on their
cytotoxic effects, but also on the ability to stimulate the
immune system. In the case of paclitaxel, there are many
postulated mechanisms for its immunostimulatory effects in
addition to tumor debulking in case of effective cytotoxic
activity, with reduction of the systemic immunosuppression
caused by malignant cells. Paclitaxel induces immunogenic
cell death through increased chromosomal content, which
causes endoplasmic stress response and calreticulin exposure,
stimulates toll-like receptor 4 increasing T cell priming by
dendritic cells, and depletes myeloid derived suppressor cells
(22, 23). Paclitaxel may also increase the antigenicity of
cancer cells by stimulating their production of interferon-β,
leading to increasing MHC class I expression (24, 25). Another
mechanism is the sensitization to cytotoxic T lymphocytes

Frontiers in Oncology | www.frontiersin.org
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FIGURE 3 | PFS by ICB treatment status (A) and in ICB-naive patients according to histology (B) and OS by ICB treatment status (C) and in ICB-naive patients
according to histology (D). ICB, immune checkpoint blocker; NE, not estimable; OS, overall survival; PFS, progression-free survival.
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FIGURE 4 | Percentage of tumor change from baseline. ICB, immune checkpoint blocker.

treatment-related TEAEs were an unexpected finding. Patients in
the nab-paclitaxel plus durvalumab arm received more treatment
cycles and a greater cumulative dose of nab-paclitaxel compared
with those who received nab-paclitaxel with or without CC486 in the randomized portion of this trial (19). Therefore, it is
reasonable to speculate that the grade 5 treatment-related TEAEs
were due, at least in part, to a greater treatment exposure with
second-line combination therapy. Although there were no grade
5 AEs reported with second-line pembrolizumab plus docetaxel
in the phase II PROLUNG trial (29), that study accrued patients
considerably younger than those treated with nab-paclitaxel plus
durvalumab in the current study (mean, 50.1 vs. 62.7 years).
Our study has several limitations. The durvalumab arm
started enrollment after the completion of the randomized nabpaclitaxel with or without CC-486, precluding a more reliable
comparison to single-agent nab-paclitaxel, and the increased
use of pembrolizumab or atezolizumab in the first-line setting
decreased the number of ICB-naive patients eligible for the nabpaclitaxel plus durvalumab combination in the clinical setting
(16–18). Furthermore, we did not collect data on PD-L1 status
of the tumors or genetic biomarkers, which are known predictors
for response to ICBs in previously untreated patients (5, 30),
although the role is not clear in patients with resistance to ICBs.
Nevertheless, despite these limitations, our study provides the
initial data on the use of nab-paclitaxel plus durvalumab after
progression on ICB, a setting with increased relevance since
the trial was designed. Despite the multiple ongoing studies
evaluating combinations involving antibodies against PD-1 or
PD-L1 with other immunostimulatory antibodies, antiangiogenic
agents and targeted drugs (31–33), none has an established role
in NSCLC patients previously treated with ICBs. Although the

TABLE 2 | Treatment-emergent adverse events occurring in at least 15% of
patients.
TEAE, n (%)

nab-Paclitaxel + Durvalumab (n = 78)
Any grade

Grade 3 or 4

Any event

78 (100.0%)

43 (55.1%)

Asthenia

36 (46.2%)

10 (12.8%)

Diarrhea

27 (34.6%)

1 (1.3%)

Decreased appetite

26 (33.3%)

1 (1.3%)

Alopecia

25 (32.1%)

0

Anemia

24 (30.8%)

4 (5.1%)

Peripheral neuropathy

29 (37.2%)

3 (3.8%)

Fatigue

22 (28.2%)

2 (2.6%)

Upper respiratory tract infection

22 (28.2%)

2 (2.6%)

Constipation

20 (25.6%)

0

Dyspnea

20 (25.6%)

6 (7.7%)

Nausea

19 (24.4%)

0

Cough

19 (24.4%)

0

Pyrexia

15 (19.2%)

0

Neutropenia

14 (17.9%)

5 (6.4%)

Lower respiratory tract infection

12 (15.4%)

1 (1.3%)

TEAE, treatment-emergent adverse event.

(16.5%) responded to the treatment, and the median PFS was
3.1 months. All patients developed grade 3 or 4 AEs, which were
mostly hematologic.
In our study, the combination of nab-paclitaxel plus
durvalumab was generally well-tolerated; however, the 4 grade 5
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